Dr James Watson

Associate Director

Co-Lead Malaria Chemoprevention Theme

james@tropmedres.ac

RESEARCH THEME(S)

Malaria

WWARN

Chagas

BIOGRAPHY

James Watson joined IDDO in March 2023 as Associate Director.

He is a Sir Henry Dale Fellow funded by the Wellcome Trust working on improving the diagnosis and treatment of severe falciparum malaria.

James is a statistician by training and previously worked at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok for seven years before moving to the Oxford University Clinical Research Unit in Viet Nam.

His research interests also include the radical cure of Plasmodium vivax malaria, SARS-CoV-2 antivirals, Chagas disease, snakebite and adaptive trial design.

Split dosing of artemisinins does not improve antimalarial therapeutic efficacy

Modelling primaquine-induced haemolysis in G6PD deficiency

Approximate models and robust decisions

The case for N-acetylcysteine in dengue associated liver injury: time for definitive evidence

Evaluating anti-infective drugs for acute illness: the legacy of Professor Sir Nicholas White

Pharmacometric evaluation of sulfadoxine-pyrimethamine- amodiaquine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda

Probabilistic classification of late treatment failure in uncomplicated falciparum malaria

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Deaths from febrile coma in African children can be reduced now

Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)

Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2

Accurate measurement of viral clearance in early phase antiviral studies in COVID-19

Assessing monoclonal antibodies for respiratory virus infections

Investigating the relationship between Pfkelch13 mutations and response to artemisinin-based treatment for uncomplicated falciparum malaria: a protocol for a systematic review and individual patient data meta-analysis

Does mass chloroquine treatment have any role in the elimination of Plasmodium vivax?

Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens

Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers.

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2

Probabilistic classification of late treatment failure in uncomplicated malaria

A protocol for a systematic review and individual patient data meta-analysis investigating the relationship between Pfkelch13 mutations and response to artemisinin-based treatment for uncomplicated falciparum malaria

Modeling the within-host dynamics of Plasmodium vivax hypnozoite activation: an analysis of the SPf66 vaccine trial

Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial

Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis

Advancing the chemotherapy of tuberculous meningitis: a consensus view

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites

Transmission-blocking activities of artesunate, chloroquine, and methylene blue on Plasmodium vivax gametocytes

Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics)

Rectal artesunate: lives not saved

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match

Where will rectal artesunate suppositories save lives?

The burden of tuberculosis in Ho Chi Minh City, Vietnam: a spatial analysis of drug-susceptible and multi-drug resistant cases between 2020 and 2023

The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis.

Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis'

Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers

Spatial analysis of drug-susceptible and multidrug-resistant cases of tuberculosis, Ho Chi Minh City, Vietnam, 2020-2023

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Modelling the within-host dynamics of Plasmodium vivax hypnozoite activation: an analysis of the SPf66 vaccine trial

Transmission-blocking activity of artesunate, chloroquine and methylene blue on Plasmodium vivax gametocytes

Within-host modelling of primaquine-induced haemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of concept trials

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency

Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis

Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Evidence based optimal dosing of intravenous artesunate in children with severe falciparum malaria

Définition d’un jeu universel de critères de décision de base pour les essais cliniques sur les morsures de serpent: traduction par Jean-Philippe Chippaux de l’article de Abouyannis M, et al. A global core outcome measurement set for snakebite clinical trials

Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)

Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency

The CARAMAL study could not assess the effectiveness of rectal artesunate in treating suspected severe malaria

Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis

Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites.

Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)

WHO should accelerate, not stall, rectal artesunate deployment for pre-referral treatment of severe malaria

A global core outcome measurement set for snakebite clinical trials

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial

Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency

Population heterogeneity in Plasmodium vivax relapse risk

The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis

The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria

Substantial misdiagnosis of severe malaria in African children

BIRC6 modifies risk of invasive bacterial infection in Kenyan children

Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria

Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis

Stopping prereferral rectal artesunate - a grave error

Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies

The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria

Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers

Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials

Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population

Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19

The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis

The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria

Asexual stage synchronicity in symptomatic and asymptomatic falciparum malaria

BIRC6 modifies risk of invasive bacterial infection in Kenyan children

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

Severe malaria, pascalian therapeutics, and the US Food and Drug Administration (FDA)

Falciparum malaria mortality in sub-Saharan Africa in the pretreatment era

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions

Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria

Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision

Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision.

Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria

Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis

Tafenoquine for the prevention of Plasmodium vivax malaria relapse

Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria

Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study

Optimal design for phase 2 studies of SARS-CoV-2 antiviral drugs

Improving the diagnosis of severe malaria in African children using platelet counts and plasma Pf HRP2 concentrations

Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria

Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials

The prognostic and diagnostic value of intraleukocytic malaria pigment: an individual patient data pooled meta-analysis of 32,000 patients with severe falciparum malaria in Africa and Asia

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions.

Is malaria parasite ex-vivo viability reduction really "superior" to observed parasite clearance rate?

Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error

Graphing and reporting heterogeneous treatment effects through reference classes

A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices

Effect of hydroxychloroquine in hospitalized patients with COVID-19

Correction to: Graphing and reporting heterogeneous treatment effects through reference classes.

COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial

Concentration-dependent mortality of chloroquine in overdose

Non-adherence in non-inferiority trials: pitfalls and recommendations

Estimating the proportion of plasmodium vivax recurrences caused by relapse: A systematic review and meta-analysis

Concentration-dependent mortality of chloroquine in overdose

A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices

Concomitant bacteremia in adults with severe falciparum malaria

A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria

A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: application to a dose-finding trial for a novel Russell’s viper antivenom in Myanmar

A semi-supervised learning framework for quantitative structure-activity regression modelling

The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos

Resolving the cause of recurrent Plasmodium vivax malaria probabilistically

Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies.

The haematological consequences of plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria

A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery

Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole

Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria

Assessing non-adherence in non-inferiority trials: implications from a simulation study

Estimating the probable cause of recurrence in Plasmodium vivax malaria: relapse, reinfection or recrudescence?

A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole

Chloroquine versus hihydroartemisinin-piperaquine with standard high-dose Primaquine given either for 7 days or 14 days in Plasmodium vivax malaria

Age, exposure and immunity

A decision theoretic approach to model evaluation in computational drug discovery

Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in plasmodium vivax malaria

Machine learning for randomised controlled trials: identifying treatment effectheterogeneity with strict control of type I error

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria

Characterising blood stage antimalarial drug minimum inhibitory concentrations in vivo using reinfection patterns

Split dosing of artemisinins does not improve antimalarial therapeutic efficacy

Antimalarial resistance unlikely to explain U.K. artemether-lumefantrine failures

Modelling primaquine-induced haemolysis in G6PD deficiency

Approximate models and robust decisions

Rejoinder: Approximate Models and Robust Decisions

Characterizing variation of nonparametric random probability measures using the Kullback–Leibler divergence

A decision theoretic approach to model evaluation in computational drug discovery

Characterising viral clearance kinetics in acute influenza

Pharmacometric evaluation of amodiaquine-sulfadoxine-pyrimethamine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda

A semi-supervised learning framework for quantitative structure-activity regression modelling

Acute kidney injury and death in severe falciparum malaria

Strong gene dose dependent protective effect of Mediterranean type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria

Graphing and reporting heterogeneous treatment effects through reference classes

Effect of higher dose primaquine for the radical cure of Plasmodium vivax malaria in Indonesia: a systematic review and individual patient data meta-analysis

Dr James Watson

BIOGRAPHY

Key Publications

Publications